Limits...
Tumor T1 Relaxation Time for Assessing Response to Bevacizumab Anti-Angiogenic Therapy in a Mouse Ovarian Cancer Model.

Ravoori MK, Nishimura M, Singh SP, Lu C, Han L, Hobbs BP, Pradeep S, Choi HJ, Bankson JA, Sood AK, Kundra V - PLoS ONE (2015)

Bottom Line: Bevacizumab treatment resulted in tumor growth inhibition (p<0.04, n=6), confirming therapeutic efficacy.Microvessel density decreased 59% and cell proliferation (Ki67+) decreased 50% in the bevacizumab treatment group (p<.001, n=6), but not apoptosis.Findings suggest that increased tumor T1 relaxation time is associated with response to bevacizumab therapy in ovarian cancer model and might serve as an early indicator of response.

View Article: PubMed Central - PubMed

Affiliation: Department of Cancer Systems Imaging, U.T.- M.D. Anderson Cancer Center, Houston, Texas, United States of America.

ABSTRACT

Purpose: To assess whether T1 relaxation time of tumors may be used to assess response to bevacizumab anti-angiogenic therapy.

Procedures: 12 female nude mice bearing subcutaneous SKOV3ip1-LC ovarian tumors were administered bevacizumab (6.25ug/g, n=6) or PBS (control, n=6) therapy twice a week for two weeks. T1 maps of tumors were generated before, two days, and 2 weeks after initiating therapy. Tumor weight was assessed by MR and at necropsy. Histology for microvessel density, proliferation, and apoptosis was performed.

Results: Bevacizumab treatment resulted in tumor growth inhibition (p<0.04, n=6), confirming therapeutic efficacy. Tumor T1 relaxation times increased in bevacizumab treated mice 2 days and 2 weeks after initiating therapy (p<.05, n=6). Microvessel density decreased 59% and cell proliferation (Ki67+) decreased 50% in the bevacizumab treatment group (p<.001, n=6), but not apoptosis.

Conclusions: Findings suggest that increased tumor T1 relaxation time is associated with response to bevacizumab therapy in ovarian cancer model and might serve as an early indicator of response.

No MeSH data available.


Related in: MedlinePlus

Histologic analysis of mean vessel density, proliferation, and apoptosis 2 weeks post-initiation of therapy.A) Immunohistochemical staining for CD31 (left) and microvessel density (right). B) Immunohistochemical staining for Ki67 (left) and Ki67 labelling index (right). C) TUNEL staining (left) and apoptotic index (right). Error bars represent standard deviation.
© Copyright Policy
Related In: Results  -  Collection

License
getmorefigures.php?uid=PMC4476738&req=5

pone.0131095.g005: Histologic analysis of mean vessel density, proliferation, and apoptosis 2 weeks post-initiation of therapy.A) Immunohistochemical staining for CD31 (left) and microvessel density (right). B) Immunohistochemical staining for Ki67 (left) and Ki67 labelling index (right). C) TUNEL staining (left) and apoptotic index (right). Error bars represent standard deviation.

Mentions: Mean vessel density, proliferation, and apoptosis were evaluated as histologic biomarkers of the effects of bevacizumab at two weeks post initiation of therapy. CD31 staining was used to mark vessels. The average mean vessel density was decreased by 59% in the bevacizumab treatment group compared to the control group (p<0.001, n = 6, Fig 5A). Ki67 was used as a marker of cellular proliferation. Ki67 labelling index was decreased by 50% in the bevacizumab treatment group (p<0.0001, Fig 5B) compared to the control group. On the other hand, apoptotic index, evaluated using TUNEL staining, was not different between the two groups (Fig 5C).


Tumor T1 Relaxation Time for Assessing Response to Bevacizumab Anti-Angiogenic Therapy in a Mouse Ovarian Cancer Model.

Ravoori MK, Nishimura M, Singh SP, Lu C, Han L, Hobbs BP, Pradeep S, Choi HJ, Bankson JA, Sood AK, Kundra V - PLoS ONE (2015)

Histologic analysis of mean vessel density, proliferation, and apoptosis 2 weeks post-initiation of therapy.A) Immunohistochemical staining for CD31 (left) and microvessel density (right). B) Immunohistochemical staining for Ki67 (left) and Ki67 labelling index (right). C) TUNEL staining (left) and apoptotic index (right). Error bars represent standard deviation.
© Copyright Policy
Related In: Results  -  Collection

License
Show All Figures
getmorefigures.php?uid=PMC4476738&req=5

pone.0131095.g005: Histologic analysis of mean vessel density, proliferation, and apoptosis 2 weeks post-initiation of therapy.A) Immunohistochemical staining for CD31 (left) and microvessel density (right). B) Immunohistochemical staining for Ki67 (left) and Ki67 labelling index (right). C) TUNEL staining (left) and apoptotic index (right). Error bars represent standard deviation.
Mentions: Mean vessel density, proliferation, and apoptosis were evaluated as histologic biomarkers of the effects of bevacizumab at two weeks post initiation of therapy. CD31 staining was used to mark vessels. The average mean vessel density was decreased by 59% in the bevacizumab treatment group compared to the control group (p<0.001, n = 6, Fig 5A). Ki67 was used as a marker of cellular proliferation. Ki67 labelling index was decreased by 50% in the bevacizumab treatment group (p<0.0001, Fig 5B) compared to the control group. On the other hand, apoptotic index, evaluated using TUNEL staining, was not different between the two groups (Fig 5C).

Bottom Line: Bevacizumab treatment resulted in tumor growth inhibition (p<0.04, n=6), confirming therapeutic efficacy.Microvessel density decreased 59% and cell proliferation (Ki67+) decreased 50% in the bevacizumab treatment group (p<.001, n=6), but not apoptosis.Findings suggest that increased tumor T1 relaxation time is associated with response to bevacizumab therapy in ovarian cancer model and might serve as an early indicator of response.

View Article: PubMed Central - PubMed

Affiliation: Department of Cancer Systems Imaging, U.T.- M.D. Anderson Cancer Center, Houston, Texas, United States of America.

ABSTRACT

Purpose: To assess whether T1 relaxation time of tumors may be used to assess response to bevacizumab anti-angiogenic therapy.

Procedures: 12 female nude mice bearing subcutaneous SKOV3ip1-LC ovarian tumors were administered bevacizumab (6.25ug/g, n=6) or PBS (control, n=6) therapy twice a week for two weeks. T1 maps of tumors were generated before, two days, and 2 weeks after initiating therapy. Tumor weight was assessed by MR and at necropsy. Histology for microvessel density, proliferation, and apoptosis was performed.

Results: Bevacizumab treatment resulted in tumor growth inhibition (p<0.04, n=6), confirming therapeutic efficacy. Tumor T1 relaxation times increased in bevacizumab treated mice 2 days and 2 weeks after initiating therapy (p<.05, n=6). Microvessel density decreased 59% and cell proliferation (Ki67+) decreased 50% in the bevacizumab treatment group (p<.001, n=6), but not apoptosis.

Conclusions: Findings suggest that increased tumor T1 relaxation time is associated with response to bevacizumab therapy in ovarian cancer model and might serve as an early indicator of response.

No MeSH data available.


Related in: MedlinePlus